Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063LOS ANGELES…
Read More